Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective

Osteoporosis International

Volumn 22, Issue 3, 2011, Pages 955-965

  Borgstrom F ^a,b   Strom O ^a,b   Kleman, M ^a   McCloskey, E ^c   Johansson, H ^d   Oden A ^d   Kanis, J A ^d  

^a Karolinska Institutet ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Clinical risk factor; Efficacy; Fracture; Osteoporosis; Risk; SERM

Indexed keywords

BAZEDOXIFENE; PLACEBO;

ADULT; AGED; ALGORITHM; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EUROPE; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; RISK REDUCTION;

AGED; AGED, 80 AND OVER; ALGORITHMS; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; HEALTH CARE COSTS; HUMANS; INDOLES; MARKOV CHAINS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 79951681025     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1291-5     Document Type: Article

References (71)

1. C Cooper EJ Atkinson SJ Jacobsen WM O'Fallon LJ Melton 3rd 1993 Population-based study of survival after osteoporotic fractures Am J Epidemiol 137 1001 1005 1:STN:280:DyaK3szgsVeltw%3D%3D 8317445 (Pubitemid 23191067)
2. SL Silverman C Christiansen HK Genant S Vukicevic JR Zanchetta TJ de Villiers GD Constantine AA Chines 2008 Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 23 1923 1934 1:CAS:528:DC%2BD1MXosVylsbo%3D 10.1359/jbmr.080710 18665787
3. E McCloskey H Johansson A Oden JA Kanis 2009 Bazedoxifene reduces all clinical fractures and morphometric vertebral fractures in postmenopausal women at increased fracture risk assessed with FRAX® Osteoporos Int 20 Suppl 2 199 200
4. JA Kanis H Johansson A Oden EV McCloskey 2009 Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 44 1049 1054 1:CAS:528:DC%2BD1MXlslWisrw%3D 10.1016/j.bone.2009. 02.014 19254788
5. O Strom F Borgstrom SS Sen S Boonen P Haentjens O Johnell JA Kanis 2007 Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial Osteoporos Int 18 1047 1061 1:STN:280:DC%2BD2sznvV2nsA%3D%3D 10.1007/s00198-007-0349-5 17333449 (Pubitemid 47020004)
6. Ström O, Coelho J, Borgstrom F, McCloskey E, Odén A, Johansson H, Kanis J (2009) Cost-effectiveness of bazedoxifene in the UK and Sweden incorporating the FRAX-algorithm Oral presentation (OC27). ECCEO, Athens
7. F Borgstrom N Zethraeus 2003 Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective Lakartidningen 100 36 40 12572135 (Pubitemid 37452914)
8. F Borgstrom O Johnell JA Kanis A Oden D Sykes B Jonsson 2004 Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study Pharmacoeconomics 22 1153 1165 10.2165/00019053-200422170-00005 15612833 (Pubitemid 39665345)
9. JA Kanis F Borgstrom O Johnell A Oden D Sykes B Jonsson 2005 Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study Osteoporos Int 16 15 25 1:STN:280:DC%2BD2M%2FksVentg%3D%3D 10.1007/s00198-004-1688-0 15672210 (Pubitemid 40193215)
10. F Borgstrom N Zethraeus O Johnell L Lidgren S Ponzer O Svensson P Abdon E Ornstein K Lunsjo KG Thorngren I Sernbo C Rehnberg B Jonsson 2006 Costs and quality of life associated with osteoporosis-related fractures in Sweden Osteoporos Int 17 637 650 10.1007/s00198-005-0015-8 16283064
11. O Ström F Borgstrom N Zethraeus O Johnell L Lidgren S Ponzer O Svensson P Abdon E Ornstein L Ceder KG Thorngren I Sernbo B Jonsson 2008 Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden Acta Orthop 79 269 280 10.1080/17453670710015094 18484255 (Pubitemid 351878360)
12. JA Kanis O Johnell A Oden B Jonsson A Dawson W Dere 2000 Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden Osteoporos Int 11 120 127 1:STN:280:DC%2BD3c3lsVeguw%3D%3D 10.1007/PL00004173 10793869 (Pubitemid 30168796)
13. CE De Laet BA van Hout H Burger A Hofman HA Pols 1997 Bone density and risk of hip fracture in men and women: cross sectional analysis Br Med J 315 221 225 (Pubitemid 27326329)
14. Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX((R)). Bone 44:1049-1054
15. McCloskey E, Johansson H, Oden A, Kanis J (2009) Bazedoxifen reduces all clinical fractures and morphometric vertebral fractures in postmenopausal women at increased fracture risk assessed with FRAX®. Oral presentation (OC32), ECCEO, Athens
16. EMEA (2009) Committee for medicinal products for human use-summary of positive opinion for Conbriza. London, 19 February
17. SR Cummings J San Martin MR McClung ES Siris R Eastell IR Reid P Delmas HB Zoog M Austin A Wang S Kutilek S Adami J Zanchetta C Libanati S Siddhanti C Christiansen 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756 765 1:CAS:528:DC%2BD1MXhtVWls7nF 10.1056/NEJMoa0809493 19671655
18. DM Black DE Thompson DC Bauer K Ensrud T Musliner MC Hochberg MC Nevitt S Suryawanshi SR Cummings 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 4118 4124 1:CAS:528:DC%2BD3cXotlWnurw%3D 10.1210/jc.85.11.4118 11095442 (Pubitemid 32055362)
19. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 922 928 10.1016/j.bone.2005.10.022 16330270 (Pubitemid 44498580)
20. E Seeman J Compston J Adachi ML Brandi C Cooper B Dawson-Hughes B Jonsson H Pols JA Cramer 2007 Non-compliance: the Achilles' heel of anti-fracture efficacy Osteoporos Int 18 711 719 1:STN:280:DC%2BD2s3mt1Sksg%3D%3D 10.1007/s00198-006-0294-8 17245547 (Pubitemid 46684777)
21. (2008) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, and strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London.
22. (2008) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London.
23. JA Kanis JE Brazier M Stevenson NW Calvert M Lloyd Jones 2002 Treatment of established osteoporosis: a systematic review and cost-utility analysis Health Technol Assess 6 1 146 1:STN:280:DC%2BD3s7jvFKgsg%3D%3D 12654239
24. I Elffors E Allander JA Kanis B Gullberg O Johnell J Dequeker G Dilsen C Gennari AA Lopes Vaz G Lyritis, et al. 1994 The variable incidence of hip fracture in southern Europe: the MEDOS Study Osteoporos Int 4 253 263 1:STN:280:DyaK2M7htFaitg%3D%3D 10.1007/BF01623349 7812073 (Pubitemid 24291433)
25. JG Brecht HP Kruse W Mohrke A Oestreich E Huppertz 2004 Health-economic comparison of three recommended drugs for the treatment of osteoporosis Int J Clin Pharmacol Res 24 1 10 1:STN:280:DC%2BD2cngtF2nsw%3D%3D 15575171 (Pubitemid 39535379)
26. BR Singer GJ McLauchlan CM Robinson J Christie 1998 Epidemiology of fractures in 15,000 adults: the influence of age and gender J Bone Joint Surg Br 80 243 248 1:STN:280:DyaK1c3gs1Ghuw%3D%3D 10.1302/0301-620X.80B2.7762 9546453 (Pubitemid 28140364)
27. JA Kanis O Johnell A Oden I Sembo I Redlund-Johnell A Dawson C De Laet B Jonsson 2000 Long-term risk of osteoporotic fracture in Malmo Osteoporos Int 11 669 674 1:STN:280:DC%2BD3M%2FlsFarsw%3D%3D 10.1007/s001980070064 11095169
28. JA Kanis A Oden O Johnell B Jonsson C de Laet A Dawson 2001 The burden of osteoporotic fractures: a method for setting intervention thresholds Osteoporos Int 12 417 427 1:STN:280:DC%2BD3MzovF2gtw%3D%3D 10.1007/s001980170112 11444092 (Pubitemid 32606468)
29. MD Silverstein JA Heit DN Mohr TM Petterson WM O'Fallon LJ Melton 3rd 1998 Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study Arch Intern Med 158 585 593 1:STN:280: DyaK1c7otVGiug%3D%3D 10.1001/archinte.158.6.585 9521222 (Pubitemid 28144815)
30. Centre for Epidemiology at the National Board of Health and Welfare, Sweden.
31. TM and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385 397 1:STN:280:DC%2BD1c7nvF2ntA%3D%3D 10.1007/s00198-007- 0543-5 18292978
32. M Lothgren N Zethraeus 2000 Definition, interpretation and calculation of cost-effectiveness acceptability curves Health Econ 9 623 630 1:STN:280:DC%2BD3M7islWnsA%3D%3D 10.1002/1099-1050(200010)9:7<623::AID- HEC539>3.0.CO;2-V 11103928
33. B Jonsson C Christiansen O Johnell J Hedbrandt G Karlsson 1996 Cost-effectiveness of fracture prevention in established osteoporosis Scand J Rheumatol Suppl 103 30 38 1:STN:280:DyaK283nt12itA%3D%3D 10.3109/ 03009749609103742 8966488 (Pubitemid 126716948)
34. F Borgstrom A Carlsson H Sintonen S Boonen P Haentjens R Burge O Johnell B Jonsson JA Kanis 2006 The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective Osteoporos Int 17 996 1007 1:STN:280:DC%2BD28zksVeltA%3D%3D 10.1007/s00198-006-0094-1 16570118 (Pubitemid 43864853)
35. F Borgstrom B Jonsson O Strom JA Kanis 2006 An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials Osteoporos Int 17 1781 1793 1:STN:280:DC%2BD28nitVSktg%3D%3D 10.1007/s00198-006-0193-z 17009083 (Pubitemid 44607399)
36. P Kind P Dolan C Gudex A Williams 1998 Variations in population health status: results from a United Kingdom national questionnaire survey Br Med J 316 736 741 1:STN:280:DyaK1c7ptVajtw%3D%3D (Pubitemid 28121072)
37. K Burstrom M Johannesson F Diderichsen 2001 Swedish population health-related quality of life results using the EQ-5D Qual Life Res 10 621 635 1:STN:280:DC%2BD38%2Fptlyhuw%3D%3D 10.1023/A:1013171831202 11822795 (Pubitemid 34056332)
38. National Osteoporosis Foundation (1998). Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int 8(Suppl 4):1-88.
39. A Oleksik P Lips A Dawson ME Minshall W Shen C Cooper J Kanis 2000 Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures J Bone Miner Res 15 1384 1392 1:STN:280:DC%2BD3M%2FhtF2jtg%3D%3D 10.1359/jbmr.2000.15.7.1384 10893688 (Pubitemid 30413872)
40. P Sobocki I Lekander F Borgstrom O Strom B Runeson 2007 The economic burden of depression in Sweden from 1997 to 2005 Eur Psychiatry 22 146 152 10.1016/j.eurpsy.2006.10.006 17194573 (Pubitemid 46507737)
41. N Zethraeus F Borgstrom B Jonsson J Kanis 2005 Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial Int J Technol Assess Health Care 21 433 441 10.1017/S0266462305050609 16262965 (Pubitemid 41642834)
42. JA Cauley DE Thompson KC Ensrud JC Scott D Black 2000 Risk of mortality following clinical fractures Osteoporos Int 11 556 561 1:STN:280: DC%2BD3crhtF2gsQ%3D%3D 10.1007/s001980070075 11069188
43. JR Center TV Nguyen D Schneider PN Sambrook JA Eisman 1999 Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 878 882 1:STN:280:DyaK1M7ptFOlug%3D%3D 10.1016/S0140-6736(98)09075-8 10093980 (Pubitemid 29126875)
44. D Bliuc ND Nguyen VE Milch TV Nguyen JA Eisman JR Center 2009 Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women JAMA 301 513 521 1:CAS:528:DC%2BD1MXhtlyqs7Y%3D 10.1001/jama.2009.50 19190316
45. A Oden A Dawson W Dere O Johnell B Jonsson JA Kanis 1998 Lifetime risk of hip fractures is underestimated Osteoporos Int 8 599 603 1:STN:280: DyaK1M3lsl2itQ%3D%3D 10.1007/s001980050105 10326067 (Pubitemid 28566977)
46. O Johnell JA Kanis A Oden I Sernbo I Redlund-Johnell C Petterson C De Laet B Jonsson 2004 Mortality after osteoporotic fractures Osteoporos Int 15 38 42 1:STN:280:DC%2BD2c%2FitlOhsw%3D%3D 10.1007/s00198-003-1490-4 14593451 (Pubitemid 38252438)
47. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ, 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res 260-265
48. Kanis J, Johnell O, Odén A, Laet CD, Jonsson B, Oglesby A (2002) Excess mortality after vertebral fracture. WHO Collaborating Centre for Metabolic Bone Diseases, Sheffield, UK.
49. MJ Parker JK Anand 1991 What is the true mortality of hip fractures? Public Health 105 443 446 1:STN:280:DyaK383gsFSisA%3D%3D 10.1016/S0033-3506(05) 80614-6 1803403
50. JA Kanis A Oden O Johnell C De Laet B Jonsson AK Oglesby 2003 The components of excess mortality after hip fracture Bone 32 468 473 1:STN:280:DC%2BD3s3jtVGhtg%3D%3D 10.1016/S8756-3282(03)00061-9 12753862 (Pubitemid 39665705)
51. NICE (2008) Osteoporosis-secondary prevention including strontium ranelate: appraisal consultation document. www.nice.org.uk
52. P Vestergaard L Rejnmark L Mosekilde 2007 Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications Osteoporos Int 18 1583 1593 1:STN:280:DC%2BD2snhs12ntg%3D%3D 10.1007/s00198-007-0403-3 17566814 (Pubitemid 47620310)
53. C Kearon 2003 Natural history of venous thromboembolism Circulation 107 I22 I30 12814982
54. Committee for medicinal products for human use (CHMP). Guidelines on the evaluation of medicinal products in the treatment of primary osteoporosis. (Lond 16 Nov 2006 CPMP/EWP/552/95 Rev.2)
55. JA Kanis J Adams F Borgstrom C Cooper B Jonsson D Preedy P Selby J Compston 2008 The cost-effectiveness of alendronate in the management of osteoporosis Bone 42 4 15 1:CAS:528:DC%2BD2sXhsVOrtrjL 10.1016/j.bone.2007.10. 019 18156107
56. TP van Staa HG Leufkens L Abenhaim B Zhang C Cooper 2000 Oral corticosteroids and fracture risk: relationship to daily and cumulative doses Rheumatology (Oxford) 39 1383 1389 10.1093/rheumatology/39.12.1383 (Pubitemid 32045866)
57. JA Kanis H Johansson O Johnell A Oden C De Laet JA Eisman H Pols A Tenenhouse 2005 Alcohol intake as a risk factor for fracture Osteoporos Int 16 737 742 10.1007/s00198-004-1734-y 15455194 (Pubitemid 40933589)
58. PD Delmas HK Genant GG Crans JL Stock M Wong E Siris JD Adachi 2003 Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial Bone 33 522 532 1:STN:280:DC%2BD3svnslSgsw%3D%3D 10.1016/S8756-3282(03)00241-2 14555255 (Pubitemid 37222378)
59. NICE (2008) Guide to the methods of technology appraisal. http://wwwniceorguk/media/B52/A7/TAMethodsGuideUpdatedJune2008pdf.
60. Borgström F, Johnell O, Kanis J, Jönsson B, Rehnberg C (2006) At what risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459-1471
61. Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. School of Health and Related Research, University of Sheffield. Sheffield
62. P Visentin R Ciravegna F Fabris 1997 Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy Maturitas 26 185 192 1:CAS:528:DyaK2sXjtlOqu7s%3D 10.1016/S0378-5122(96)01099-7 9147350 (Pubitemid 27209950)
63. N Zethraeus O Strom F Borgstrom 2006 What is the risk of institutionalization after hip fracture? Osteoporos Int 17 Suppl 1 57 58
64. A Gordois J Posnett L Borris P Bossuyt B Jonsson E Levy G de Pouvourville 2003 The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery J Thromb Haemost 1 2167 2174 1:CAS:528:DC%2BD2cXktFOltbw%3D 10.1046/j.1538-7836.2003. 00396.x 14521600
65. G Kobelt J Berg P Lindgren G Izquierdo O Sanchez-Solino J Perez-Miranda MA Casado 2006 Costs and quality of life of multiple sclerosis in Spain Eur J Health Econ 7 Suppl 2 S65 S74 10.1007/s10198-006-0381-y 17310340
66. Stockholms stads budgetavräkning (2003) [online]. [cited 2004-12-20]. Available from: www.stockholm.se/files/71600-71699/file-71645.pdf
67. Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047-1061 (Pubitemid 47020004)
68. L'assurance maladie en ligne 2004.
69. F Lordick B Ehlken A Ihbe-Heffinger K Berger KJ Krobot J Pellissier G Davies R Deuson 2007 Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany Eur J Cancer 43 299 307 1:CAS:528:DC%2BD2sXpvVKrsQ%3D%3D 10.1016/j.ejca.2006.09.019 17134890 (Pubitemid 46123990)
70. S Capri S Perlini 2005 Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events Curr Med Res Opin 21 913 921 10.1185/030079905X46331 16003858 (Pubitemid 40896239)
71. Curtis L, Unit Costs of Health and Social Care (2008) [online]. [cited 2009-02-03]. Personal Social Services Research Unit: University of Kent, Available from: http://www.pssru.ac.uk/uc/uc.htm